Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
EMTRICITABINE vs LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by competing with natural substrates and causing chain termination. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (lamivudine 300 mg; zidovudine 300 mg; efavirenz 600 mg) orally once daily on an empty stomach, preferably at bedtime.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Lamivudine: 5-7 hours in adults (prolonged in renal impairment). Zidovudine: 0.5-3 hours (terminal half-life), with intracellular active triphosphate half-life ~3 hours. Efavirenz: 40-55 hours (single dose), 10-20 hours at steady state (due to autoinduction), supporting once-daily dosing.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Lamivudine: renal (approximately 70% unchanged via glomerular filtration and active tubular secretion). Zidovudine: renal (approximately 14% unchanged, major metabolite G-ZDV 60-80% excreted in urine). Efavirenz: hepatic metabolism (CYP2B6, CYP3A4) with fecal (14-34%) and urinary (<1%) elimination.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."